Equillium

Update in progress

EQ (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Equillium, Inc. is a clinical-stage biotechnology company focused on therapies for severe autoimmune and inflammatory diseases in the United States. It advances EQ504, a novel AhR modulator in preclinical development for ulcerative colitis and lung inflammation, and EQ302, a bispecific IL-15/IL-21 inhibitor designed for oral delivery to treat celiac disease. Formerly Attenuate Biopharmaceuticals, it renamed in May 2017 and is headquartered in La Jolla, California.

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive